

Peter Ellmark
Institutionen för immunteknologi
LUCC: Lunds universitets cancercentrum
Adresstyp: Besöksadress.
Medicon Village, Scheelevägen 2
Lund
Sverige
Adresstyp: Postadress.
Box 118
221 00
Lund
Sverige
Adresstyp: Postadress.
Lunds Universitet, Box 117
221 00
Sverige
E-post: peter.ellmark@immun.lth.se
Telefon: +46462864280
Webbadress: <http://www.immun.lth.se>



Forskningsoutput

REACTiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

Kucukcelebi, S., van 't Land, F. R., van der Burg, S. H., Eskens, F. A. L. M., Homs, M. Y. V., Willemsen, M., Onrust-van Schoonhoven, A., Rozendaal, N. E. M., Fella, A., Vadgama, D., Moskie, M., Bezemer, K., Doukas, M., van Eijck, C. W. F., Stadhouders, R., de Vos-Geelen, J., van Diepen, A. E., Enninga, I., Meijer, R. & Ambarkhane, S. V. och 4 andra, Ellmark, P., Aerts, J. G. J. V., Groeneveldt, C. & van Eijck, C. H. J., 2025 nov. 28, I: Nature Communications. 16, 15 s., 10609.

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

Van Laethem, J.-L., Geboes, K., Borbath, I., Macarulla Mercade, T., Lambert, A., Cassier, P., Prenen, H., Mitry, E., Blanc, J.-F., Pilla, L., Feliu, J., Rodriguez Garrote, M., Pazo-Cid, R. A., Gallego, I., Smith, K. E., Nordbladh, K., Jimenez, D. G., Ellmark, P., Pico de Coaña, Y. & Ambarkhane, S. V. och 2 andra, Beatty, G. L. & O'Reilly, E. M., 2025 okt. 21, I: Cell Reports Medicine. 6, 10, 102407.

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

Carneiro, A., Hahn, A., Ellmark, P., Enell Smith, K., Schultz, L., Ambarkhane, S., Yachnin, J. & Ullenhag, G. J., 2025 jan. 22, I: Journal for ImmunoTherapy of Cancer. 13

Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform

Nyesiga, B., Hägerbrand, K., Varas, L., Gjørloff Wingren, A., Ohlin, M., Ellmark, P. & von Schantz, L., 2025, I: Drug delivery. 32, 1, 2486340.

ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell-dependent tumor immunity and synergizes with PD-1 blockade

Andersson, H., Uddbäck, I., Hermodsson, T., Celandner, M., Krishna Shetty, A., Ljung, L., Nilsson, A., Sundstedt, A., von Schantz, L., Varas, L. A., Levin, M., Säll, A., Weilguny, D., Jansson, K., Fritzell, S., Hägerbrand, K., Lindstedt, M. & Ellmark, P., 2025, I: Cancer immunology research. 13, 12, s. 1987-2003 31 s.

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

Van Laethem, J. L., Borbath, I., Prenen, H., Geboes, K. P., Lambert, A., Mitry, E., Cassier, P. A., Blanc, J. F., Pilla, L., Battle, J. F., Garrote, M. R., Pazo-Cid, R. A., Gallego, I., Smith, K. E., Ellmark, P., Pico de Coaña, Y., Ambarkhane, S. V. & Macarulla, T., 2024 juli, I: The Lancet Oncology. 25, 7, s. 853-864 12 s.

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes

Sincic, V., Arlenhold, K. F., Richtmann, S., Lilljebjörn, H., Eriksson, P., Sjö Dahl, G., Wokander, M., Hägerbrand, K., Ellmark, P., Fioretos, T., Borrebaeck, C. A. K., Liedberg, F. & Lundberg, K., 2024 juni, I: Cells. 13, 11, 926.

CD4 effector T cell expansion to identify objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX (mFFX) as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) in the OPTIMIZE-1 study

Wattenberg, M. M., Smith, K. E., de Coaña, Y. P., Jimenez, D. G., Ambarkhane, S. V., Ellmark, P. & Beatty, G. L., 2024.

Next-generation CD40 agonists for cancer immunotherapy

Andersson, H., Nyesiga, B., Hermodsson, T., Enell Smith, K., Hägerbrand, K., Lindstedt, M. & Ellmark, P., 2024, I: Expert Opinion on Biological Therapy. 24, 5, s. 351-363 13 s.

ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1

Enell Smith, K., Fritzell, S., Nilsson, A., Barchan, K., Rosén, A., Schultz, L., Varas, L., Säll, A., Rose, N., Håkansson, M., von Schantz, L. & Ellmark, P., 2023 dec., I: Cancer Immunology, Immunotherapy. 72, 12, s. 4145-4159 15 s.

Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody

Andersson, H., Sobti, A., Jimenez, D. G., de Coaña, Y. P., Ambarkhane, S. V., Hägerbrand, K., Smith, K. E., Lindstedt, M. & Ellmark, P., 2023 okt., I: Cells. 12, 19, 2365.

The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies

Nelson, M. H., Fritzell, S., Miller, R., Werchau, D., Van Citters, D., Nilsson, A., Misher, L., Ljung, L., Bader, R., Deric, A., Chunyk, A. G., Schultz, L., Varas, L. A., Rose, N., Håkansson, M., Gross, J., Furebring, C., Pavlik, P., Sundstedt, A. & Veitonmäki, N. och 9 andra, Ramos, H. J., Säll, A., Dahlman, A., Bienvenue, D., von Schantz, L., McMahan, C. J., Askmyr, M., Hernandez-Hoyos, G. & Ellmark, P., 2023 jan. 3, I: Molecular Cancer Therapeutics. 22, 1, s. 89-101 13 s.

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

Hägerbrand, K., Varas, L., Deric, A., Nyesiga, B., Sundstedt, A., Ljung, L., Sakellariou, C., Werchau, D., Thagesson, M., Gomez Jimenez, D., Greiff, L., Celander, M., Smedenfors, K., Rosén, A., Bölükbas, D., Carlsson, F., Levin, M., Säll, A., Von Schantz, L. & Lindstedt, M. och 1 andra, Ellmark, P., 2022 nov. 2, I: Journal for Immunotherapy of Cancer. 10, 11, e005018.

Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia

Abolhalaj, M., Sincic, V., Lilljebjörn, H., Sandén, C., Aab, A., Hägerbrand, K., Ellmark, P., Borrebaeck, C., Fioretos, T. & Lundberg, K., 2022, I: Cancer Medicine. 11, 15, s. 3023-3032

CD137 (4-1BB) costimulation of CD8⁺ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

Otano, I., Azpilikueta, A., Glez-Vaz, J., Alvarez, M., Medina-Echeverez, J., Cortés-Domínguez, I., Ortiz-de-Solorzano, C., Ellmark, P., Fritzell, S., Hernandez-Hoyos, G., Nelson, M. H., Ochoa, M. C., Bolaños, E., Cuculescu, D., Jaúregui, P., Sanchez-Gregorio, S., Etxeberria, I., Rodriguez-Ruiz, M. E., Sanmamed, M. F. & Teijeira, Á. och 2 andra, Berraondo, P. & Melero, I., 2021 dec. 1, I: Nature Communications. 12, 1, 7296.

Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

Enell Smith, K., Deric, A., Hägerbrand, K., Norlén, P. & Ellmark, P., 2021, I: Expert Opinion on Biological Therapy. 21, 12, s. 1635-1646

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo

Deric, A., Nilsson, A., Thagesson, M., Werchau, D., Enell Smith, K. & Ellmark, P., 2021, I: Cancer Immunology, Immunotherapy. 70, 12, s. 3629-3642

Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer.

Sincic, V., Abolhalaj, M., Lilljebjörn, H., Aab, A., Hägerbrand, K., Ellmark, P., Fioretos, T., Borrebaeck, C., Liedberg, F. & Lundberg, K., 2020, I: *Journal for ImmunoTherapy of Cancer*. 8, Suppl. 3

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Georganaki, M., Ramachandran, M., Tuit, S., Núñez, N. G., Karampatzakis, A., Fotaki, G., van Hooren, L., Huang, H., Lugano, R., Ulas, T., Kaunisto, A., Holland, E. C., Ellmark, P., Mangsbo, S. M., Schultze, J., Essand, M., Tugues, S. & Dimberg, A., 2020, I: *Oncolmmunology*. 9, 1, 14 s., 1730538.

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

Irenaeus, S. M. M., Nielsen, D., Ellmark, P., Yachnin, J., Deric, A., Nilsson, A., Norlén, P., Veitonmäki, N., Wennersten, C. S. & Ullenhag, G. J., 2019 sep. 1, I: *International Journal of Cancer*. 145, 5, s. 1189-1199 11 s.

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Kvarnhammar, A. M., Veitonmäki, N., Hägerbrand, K., Dahlman, A., Smith, K. E., Fritzell, S., Von Schantz, L., Thagesson, M., Werchau, D., Smedenfors, K., Johansson, M., Rosén, A., Åberg, I., Winnerstam, M., Nyblom, E., Barchan, K., Furebring, C., Norlén, P. & Ellmark, P., 2019 apr. 11, I: *Journal for ImmunoTherapy of Cancer*. 7, 1

Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression

Hebb, J. P. O., Mosley, A. R., Vences-Catalán, F., Rajasekaran, N., Rosén, A., Ellmark, P. & Felsner, D. W., 2018 jan., I: *Cancer Immunology, Immunotherapy*. 67, 1, s. 47-60

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

van Hooren, L., Sandin, L. C., Moskalev, I., Ellmark, P., Dimberg, A., Black, P., Tötterman, T. H. & Mangsbo, S. M., 2017 feb., I: *European Journal of Immunology*. 47, 2, s. 385-393

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

Ellmark, P., Mangsbo, S. M., Furebring, C., Norlén, P. & Tötterman, T. H., 2017 jan., I: *Cancer Immunology and Immunotherapy*. 66, 1, s. 1-7 s.

Selective FcγR engagement by human agonistic anti-CD40 antibodies

Ellmark, P., Mangsbo, S. M. & Lindstedt, M., 2016, I: *Translational Cancer Research*. 5, s. S839-S841

Kick-starting the cancer-immunity cycle by targeting CD40

Ellmark, P., Mangsbo, S. M., Furebring, C., Tötterman, T. H. & Norlén, P., 2015, I: *Oncolmmunology*. 4, 7, s. e1011484

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity.

Mangsbo, S. M., Broos, S., Fletcher, E., Veitonmaki, N., Furebring, C., Dahlen, E., Norlén, P., Lindstedt, M., Tötterman, T. H. & Ellmark, P., 2015, I: *Clinical Cancer Research*. 21, 5, s. 1115-1126

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A. S., Tötterman, T. H. & Mangsbo, S. M., 2014, I: *Oncolmmunology*. 3, 1, s. e27614

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.

Sandin, L. C., Orlova, A., Gustafsson, E., Ellmark, P., Tolmachev, V., Tötterman, T. H. & Mangsbo, S. M., 2014, I: *Cancer immunology research*. 2, 1, s. 80-90

Atto-vial-based antibody nanoarrays.

Ellmark, P., Ghatnekar-Nilsson, S., Meister, A., Heinzemann, H., Montelius, L., Wingren, C. & Borrebaeck, C., 2009, I: *Proteomics*. 9, 24, s. 5406-5413

Detection of pancreatic cancer using antibody microarray-based serum protein profiling

Ingvarsson, J., Wingren, C., Carlsson, A., Ellmark, P., Wahren, B., Engström, G., Harmenberg, U., Krogh, M., Peterson, C. & Borrebaeck, C., 2008, I: *Proteomics*. 8, 11, s. 2211-2219

Identification of a strongly activating human anti-CD40 antibody that suppresses HIV-1 infection

Ellmark, P., Andersson, H., Abayneh, S., Fenyö, E. M. & Borrebaeck, C., 2008, I: *AIDS Research and Human Retroviruses*. 24, 3, s. 367-373

Multiplexed Lipid Dip-Pen Nanolithography on Subcellular Scales for the Templating of Functional Proteins and Cell Culture

Sekula, S., Fuchs, J., Weg-Remers, S., Nagel, P., Schuppler, S., Fragala, J., Theilacker, N., Franueb, M., Wingren, C., Ellmark, P., Borrebaeck, C., Mirkin, C. A., Fuchs, H. & Lenhart, S., 2008, I: *Small*. 4, 10, s. 1785-1793

Phenotypic protein profiling of different B cell sub-populations using antibody CD-microarrays

Ellmark, P., Högerkorp, C.-M., Ek, S., Beelov, L., Berglund, M., Rosenquist, R., Christopherson, R. & Borrebaeck, C., 2008, I: *Cancer Letters*. 265, s. 98-106

Sensitivity of HIV-1 primary isolates to human anti-CD40 antibody-mediated suppression is related to co-receptor use

Abayneh, S. A., Ellmark, P., Karlsson, U., Andersson, H., Borrebaeck, C., Karlsson, I. & Fenyö, E. M., 2008, I: *AIDS Research and Human Retroviruses*. 24, 3, s. 447-452

Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.

Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldetorp, B., Fernö, M., Olsson, H. & Borrebaeck, C., 2008, I: *European Journal of Cancer*. 44, 3, s. 472-480

The Applicability of a Cluster of Differentiation Monoclonal Antibody Microarray to the Diagnosis of Human Disease

Ellmark, P., Woolfson, A., Belov, L. & Christopherson, R. I., 2008, I: *Methods in Molecular Biology*. 439, s. 199-209

Antibody microarray based oncoproteomics - analysis of breast cancer proteomes

Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldetorp, B., Fernö, M., Olsson, H. & Borrebaeck, C., 2007, I: *Proceedings of the PEPTALK 2007 meeting*.

Development of atto-vial based antibody arrays

Ghatnekar-Nilsson, S., Ellmark, P., Wingren, C., Dexlin Mellby, L., Montelius, L. & Borrebaeck, C., 2007.

Development of atto-vial based antibody arrays

Ellmark, P., Ghatnekar-Nilsson, S., Wingren, C. & Borrebaeck, C., 2007.

Development of atto-vial based antibody arrays

Ellmark, P., Ghatnekar-Nilsson, S., Wingren, C., Dexlin Mellby, L., Montelius, L. & Borrebaeck, C., 2007.

Recombinant antibody microarray based oncoproteomics detects cancer and defines a predictor of survival for pancreatic carcinoma

Ingvarsson, J., Wingren, C., Carlsson, A., Ellmark, P., Wahren, B., Engström, G., Harmenberg, U., Krogh, M., Peterson, C. & Borrebaeck, C., 2007, I: *Molecular & Cellular Proteomics*. s. S311

Serum protein profiling of metastatic breast cancer

Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldetorp, B., Fernö, M., Olsson, H. & Borrebaeck, C., 2007, I: *Molecular & Cellular Proteomics*. October, s. S311

Antibody microarray based oncoproteomics - analysis of breast cancer proteomes

Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldetorp, B., Fernö, M., Olsson, H. & Borrebaeck, C., 2006, I: Proceedings of the 29th annual San Antonio breast cancer symposium.

High-throughput membrane proteomics using recombinant antibody microarrays

Dexlin Mellby, L., Ingvarsson, J., Karlsson, J., Ellmark, P., Frendeus, B., Borrebaeck, C. & Wingren, C., 2006, I: Molecular & Cellular Proteomics. 5, 10, s. S70

Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays

Ellmark, P., Ingvarsson, J., Carlsson, A., Lundin, B. S., Wingren, C. & Borrebaeck, C., 2006, I: Molecular & Cellular Proteomics. 5, 9, s. 1638-1646

Multiplex detection of surface molecules on colorectal cancers

Ellmark, P., Belov, L., Huang, P., Lee, S., Solomon, M., Morgan, D. & Christopherson, R., 2006, I: Proteomics. 6, 6, s. 1791-1802

Protein expression profiling in normal and malignant stomach tissue using recombinant antibody microarrays

Ellmark, P., Ingvarsson, J., Carlsson, A., Lundin, S., Svennerholm, A.-M., Wingren, C. & Borrebaeck, C., 2006.

Protein expression profiling using recombinant antibody microarrays

Ellmark, P., Ingvarsson, J., Carlsson, A., Lundin, S., Svennerholm, A.-M., Wingren, C. & Borrebaeck, C., 2006.

The application of CD antigen proteomics to pharmacogenomics

Woolfson, A., Ellmark, P., Chrisp, J. S., Scott, M. A. & Christopherson, R. I., 2006, I: Pharmacogenomics. 7, 5, s. 759-771

Protein expression profiling in normal and malignant stomach tissue using recombinant antibody microarrays

Ellmark, P., Ingvarsson, J., Carlsson, A., Lundin, S., Svennerholm, A.-M., Wingren, C. & Borrebaeck, C., 2005.

A novel mammalian display system for the selection of protein-protein interactions by decoy receptor engagement

Ellmark, P., Ohlin, M., Borrebaeck, C. & Furebring, C., 2004, I: Journal of Molecular Recognition. 17, 4, s. 316-322

Profiling of internalizing tumor-associated antigens on breast and pancreatic cancer cells by reversed genomics

Fransson, J., Ek, S., Ellmark, P., Söderlind, E., Borrebaeck, C. & Furebring, C., 2004, I: Cancer Letters. 208, 2, s. 235-242

Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies

Malmberg Hager, A.-C., Ellmark, P., Borrebaeck, C. & Furebring, C., 2003, I: Scandinavian Journal of Immunology. 57, 6, s. 517-524

Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosis

Ellmark, P., Furebring, C. & Borrebaeck, C., 2003, I: Immunology. 108, 4, s. 452-457

Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of naïve B-cells from anti-IgM induced apoptosis

Ellmark, P., Borrebaeck, C. & Furebring, C., 2003, (Unpublished) s. W14.01.

In vitro molecular evolution of antibody genes mimicking receptor revision

Ellmark, P., Esteban, O., Furebring, C., Malmberg Hager, A.-C. & Ohlin, M., 2002, I: Molecular Immunology. 39, 5-6, s. 349-356

Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library

Ellmark, P., Ottosson, C., Borrebaeck, C., Malmberg Hager, A.-C. & Furebring, C., 2002, I: Immunology. 106, 4, s. 456-463

The CD40 Receptor - Target, Tool and Technology

Ellmark, P., 2002, 150 s.